Assessment of ATRX Expression in Patients With Myelodysplastic Syndromes Treated with Decitabine

Por Steensma, David P., Porcher, Julie C., Litzow, Mark R., Hogan, William J., Arora, Sujata, Van Laar, Emily
Publicado em 2009

Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy

Por Chasen, Martin, Urban, Laszlo, Schnadig, Ian, Rapoport, Bernardo, Powers, Dan, Arora, Sujata, Navari, Rudolph, Schwartzberg, Lee, Gridelli, Cesare
Publicado no Support Care Cancer (2016)

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

Por Hesketh, Paul J., Schnadig, Ian D., Schwartzberg, Lee S., Modiano, Manuel R., Jordan, Karin, Arora, Sujata, Powers, Dan, Aapro, Matti
Publicado no Cancer (2016)

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

Por Steensma, David P., Baer, Maria R., Slack, James L., Buckstein, Rena, Godley, Lucy A., Garcia-Manero, Guillermo, Albitar, Maher, Larsen, Julie S., Arora, Sujata, Cullen, Michael T., Kantarjian, Hagop
Publicado no J Clin Oncol (2009)